DexteraAI uses AI-enabled surgical video analysis to quantify subretinal delivery performance in gene and cell therapy trials.
We measure how the instrument behaves during the critical delivery step — including precision, smoothness, instability, tremor, and correction burden — to help sponsors evaluate whether surgical delivery performance relates to procedural outcomes, safety, imaging findings, or visual results.
Initial focus: subretinal therapeutic trials in wet AMD, dry AMD / geographic atrophy, and retinal gene and cell therapy programs requiring surgical delivery.
DexteraAI converts routine surgical video into objective, quantitative measures of surgical execution, helping gene and cell therapy sponsors identify, manage, and reduce procedural variability in high-risk subretinal trials.
Outcomes may reflect surgical technical performance — not only the biologic, dose, or patient anatomy. That variability is rarely quantified.
Learn more →DexteraAI converts surgical video into quantitative measures of instrument-tip precision, smoothness, instability, and tremor.
Learn more →Retinal gene and cell therapy programs requiring subretinal delivery — focused on the critical delivery maneuver in wet AMD, GA, and inherited retinal disease.
Learn more →DexteraAI's initial focus is retinal gene and cell therapy programs requiring subretinal delivery. These trials involve high-value biologic products, technically demanding surgical administration, and narrow regulatory and adoption pathways because established intravitreal therapies already exist for major retinal diseases.
The initial use case is not broad surgical video review. It is focused analysis of the critical subretinal delivery maneuver.
Four applications spanning pre-pivotal analysis through post-market surgeon quality assurance.
Evaluate whether delivery-performance metrics are associated with sponsor-defined procedural, safety, imaging, or clinical endpoints.
Track whether technical-performance profiles remain stable across surgeons, sites, cases, and time.
Assess whether surgical technical variability may have contributed to efficacy, safety, or durability variability.
Support objective, video-derived feedback for surgeon onboarding, credentialing, retraining, and post-market monitoring.
Whether you are planning a pivotal trial or interpreting a completed one, DexteraAI can quantify subretinal delivery performance and evaluate it against your sponsor-defined procedural and clinical endpoints.